Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Rating) has earned a consensus rating of “Buy” from the seven research firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $30.40.
Several equities analysts recently issued reports on GLUE shares. Zacks Investment Research raised Monte Rosa Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 17th. Wells Fargo & Company initiated coverage on Monte Rosa Therapeutics in a research report on Thursday, February 10th. They issued an “equal weight” rating and a $19.00 target price on the stock. Finally, Guggenheim lowered their price target on shares of Monte Rosa Therapeutics from $40.00 to $35.00 in a report on Monday, January 3rd.
Large investors have recently bought and sold shares of the business. Royal Bank of Canada purchased a new stake in Monte Rosa Therapeutics in the third quarter valued at $29,000. Citigroup Inc. purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $29,000. Piper Sandler & CO. purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $51,000. Strs Ohio purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $60,000. Finally, Legal & General Group Plc boosted its stake in shares of Monte Rosa Therapeutics by 206.6% during the 4th quarter. Legal & General Group Plc now owns 3,317 shares of the company’s stock worth $68,000 after acquiring an additional 2,235 shares in the last quarter. 72.50% of the stock is currently owned by institutional investors.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.43). On average, analysts predict that Monte Rosa Therapeutics will post -2.28 earnings per share for the current year.
Monte Rosa Therapeutics Company Profile (Get Rating)
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.